(VOVWORLD) - Pfizer Inc. and BioNTech SE on Friday asked US regulators to authorize their COVID-19 vaccine for emergency use in children aged 5-11.
 Pfizer BioNTech vaccine (Photo: AFP/VNA) |
In late September, Pfizer and BioNTech published the results of its clinical trial conducted on 2,268 volunteers, which revealed strong immune response and high safety level in children aged 5-11. The joint venture intends to also seek authorization in other countries. It is studying vaccine efficacy in babies (6 months to 2 years) and children aged 2-5. Preliminary results of trials on these age groups are expected by year end.